Find insights on China’s healthcare sector, Thomson Medical Group, Cochlear, and more in the latest Market Talks covering the ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing unit to New York-based Altaris LLC, easing worries that federal limits ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

On the mainland, the CSI 300 Index climbed 0.5 per cent, while the Shanghai Composite Index rose ... Other big gainers included pharmaceutical company WuXi AppTec, which surged 7.2 per cent ...

Since Beijing and Washington imposed tariffs on each other's goods this month, Western media have been closely monitoring whether the trade war will ...

WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...